Interferon alpha for the adjuvant treatment of melanoma: Review of international literature and practical recommendations from an expert panel on the use of interferon

Journal of Chemotherapy

Volumn 26, Issue 4, 2014, Pages 193-201

  Ascierto, Paolo A ^a   Chiarion Sileni, Vanna ^b   Muggiano, Antonio ^c   Mandalà, Mario ^d   Pimpinelli, Nicola ^e   Del Vecchio, Michele ^f   Rinaldi, Gaetana ^g   Simeone, Ester ^a   Queirolo, Paola ^h  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Struttura Semplice Dipartimentale Melanoma e Patologie Rare ASL8   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

Author keywords

Adjuvant therapy; Interferon alpha 2b; Melanoma

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; DABRAFENIB; FOLFOX; IPILIMUMAB; PEGINTERFERON; PLATINUM; PROTEIN S100B; STAT1 PROTEIN; STAT3 PROTEIN; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

BREAST CANCER; CANCER STAGING; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; FOLLOW UP; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; LUNG CANCER; LYMPH NODE METASTASIS; MELANOMA; META ANALYSIS (TOPIC); OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; ULCER; ADJUVANT CHEMOTHERAPY; META ANALYSIS;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; INTERFERON-ALPHA; MELANOMA;

EID: 84903388549     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000154     Document Type: Review

References (46)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST1684. J Clin Oncol. 1996;14:7-17.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
3. Robert C, Thomas L, Bondarenko I, O'Day S, Garbe C, Lebbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
5. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-65.
6. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAFmutated melanoma. N Engl J Med. 2012;367:107-14.
7. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117-26.
8. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.
9. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206.
10. Gershenwald JE, Soong SJ, Balch CM, American Joint Committee on Cancer (AJCC) Melanoma Staging Committee. 2010 TNM staging system for cutaneous melanoma... and beyond. Ann Surg Oncol. 2010;17:1475-7.
11. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17.
12. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351:1905-10.
13. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16:1425-9.
14. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/ S9111/C9190. J Clin Oncol. 2000;18:2444-58.
15. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102:493-501.
16. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29:241-52.
17. Wheatley K, Ives N, Eggermont A, Kirkwood J, Cascinelli N, Markovic SN, et al. Interferon-as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol. 2007;25 [ASCO Annual Meeting Proceedings Part I 2007: abstract 8526].
18. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med. 2008;6:62.
19. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006;24:3164-71.
20. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFN alpha2b. Clin Cancer Res. 2007;13:1523-31.
21. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-18.
22. Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant highdose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009;27:939-44.
23. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/ C509801. J Clin Oncol. 2001;19:2370-80.
24. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007;13:2422-88.
25. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, et al. Characterization of CD4zCD25z regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169-77.
26. Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, et al. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med. 2010;8:76.
27. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007;4:e176.
28. Simons DL, Lee G, Kirkwood JM, Lee PP. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med. 2011;9:52.
29. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358:866-9.
30. Cascinelli N, Bufalino R, Morabito A, Mackie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994;343:913-4.
31. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomized controlled trial. Lancet. 2005;366:1189-96.
32. Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, et al. Ulceration and stage are predictive of interferon efficacy in melanoma. Results of the phase III adjuvant trials EORTC 18952 and EORTC18991. Eur J Cancer. 2012;48:218-25.
33. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13:2776-83.
34. Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, et al. Adjuvant low-dose interferon (alpha) 2a with or without dacarbazine compared with surgery alone: a prospectiverandomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008;19:1195-201.
35. Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Bottjer J, et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol. 2010;28:841-6.
36. Grob JJ, Jouary T, Dréno B, Asselineau J, Gutzmer R, Hauschild A, et al. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer. 2013;49:166-74.
37. Chiarion-Sileni V, Guida M, Romanini A, Ridolfi R, Mandala M, Del Bianco P, et al. Intensified highdose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: a randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]. J Clin Oncol. 2011;29:abstract 8506.
38. Mohr P, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, et al. Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: final analysis of a randomized phase III DeCOGtrial (NCT00226408). J Clin Oncol. 2012;30:abstract 8504.
39. Mohr P, Hauschild A, Trefzer U, Weichenthal M. Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma. J Clin Oncol. 2009;27:e70.
40. Agarwala SS, Lee SJ, Flaherty LE, Smylie M, Kefford RF, Carson III WE, et al. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate-and high-risk melanoma (Intergroup trial E 1697). J Clin Oncol. 2011;29:abstract 8505.
41. Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, et al. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph nodenegative melanoma. J Clin Oncol. 2009;27:3496-502.
42. Ascierto PA, Gogas HJ, Grob JJ, Algarra SM, Mohr P, Hansson J, et al. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit Rev Oncol Hematol. 2013;85:149-61.
43. Cameron DA, Cornbleet MC, Mackie RM, Hunter JA, Gore M, Hancock B, et al. Adjuvant interferon alpha 2b in high risk melanoma: the Scottish study. Br J Cancer. 2001;84: 1146-9.
44. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22:53-61.
45. Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, et al. Final results of the ORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADORM versus observation after surgery in melanoma patients with either high-risk primary (thickness.3 mm) or regional lymph node metastasis. Eur J Cancer. 2004;40:390-402.
46. Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with highrisk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 2011;12:144-52.